Vivet Therapeutics to Present Key Findings on its Gene Therapy Program forCerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
Paris, France, November 14, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotechcompany developing novel and long-lasting gene therapies for rare inherited liver metabolicdisorders, today announces that it will be presenting key pre-clinical findings for VTX-806, itsgene therapy program for the treatment of Cerebrotendinous Xanthomatosis (CTX), at TheLiver Meeting presented by the American Association for […]
💗Pink October💗
In collaboration with @Courir pour Elles, @Vivet_tx participated in an 8km walk/run to raise #BreastCancer Awareness and Prevention. Join #TeamVivet in the cause as we rack up steps👟for #CourirPourElles’ 💗Pink 💗Challenge during #PinkOctober. Also known as ‘le Défi Rose’, the Challenge helps raise #BreastCancerAwareness and highlights the role a healthy lifestyle plays in #cancer prevention.
Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
Paris, France, October 22, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the presentation of three posters demonstrating key pre-clinical findings for its gene therapy program, VTX-806 for the treatment of Cerebrotendinous Xanthomatosis (CTX), a study on S/MAR-containing AAV vector […]
Leukodystrophy Awareness Month
📢 Leukodystrophy Awareness Month takes place throughout the whole month of September and is a time to raise awareness about these devastating rare conditions! Together 🤝 let’s shine a light💡 and increase understanding of leukodystrophy, a group of rare genetic metabolic disorders affecting the central nervous system. Leukodystrophies are characterized by the abnormal growth of […]
The @European Commission has granted Orphan Drug Designation (#ODD) to our gene therapy product, VTX-806, for the treatment of cerebrotendinous xanthomatosis (#CTX), a rare #neurodegenerativedisease in patients.
European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis (CTX) • Pre-clinical data of VTX-806 in mice demonstrated normalization of metabolic parameters in blood and brain, and of upregulated compensatory enzymes• EUR 4.9 million funding provided by French Government to develop VTX-806 as an effective treatment […]
Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science
Paris, France, July 16, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, is delighted to announce that its Co-Founder & Chief Scientific Officer, Dr Gloria Gonzalez-Aseguinolaza, PhD, has been honored with the Rosalind Franklin Society (RFS) Special Award in Science given […]
Characteristics of patients with Wilson Disease in the United States: An insurance claims database study
We are delighted to share our findings in a peer reviewed paper published in the World Journal of Hepatology, titled ‘Characteristics of patients with Wilson Disease in the United States: An insurance claims database study.’
Vivet Therapeutics presents interim data on its Phase 1/2 GATEWAY trial for the Treatment of Wilson Disease at EASL Congress 2024
Vivet Therapeutics Presents Interim Data from its Phase 1/2 GATEWAY Trial for the Treatment of Wilson Disease at EASL Congress 2024 VTX-801 increased ceruloplasmin ferroxidase activity and improved liver histology
Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology
Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders,
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease
